Pharma's Patience Pays Off: Patient Advocates Are Powerful Allies in Part D

01 Jun 2006

• By Kate Rawson

The pharmaceutical industry has long counted on patient advocates as allies in the FDA drug approval process. But their relationship on issues related to drug coverage has often been tense. The Medicare drug benefit has opened a new chapter in the relationship. Patient advocates have worked closely with the Centers for Medicare & Medicaid Services in the early months of Part D, and they have had an impact. Industry's long-time effort to establish alliances is paying off.

At the start of 2006, it looked like Pfizer Inc. might have a big headache in positioning pregabalin (Lyrica) under the newly implemented Medicare Part D drug benefit. The epilepsy drug is one of Pfizer’s most important new products, but when formulary information for Part D was first made public, Lyrica was nowhere to be found. In other words, Pfizer faced the prospect of missing out on a lucrative new prescription drug market.

Lyrica’s coverage profile was something the Epilepsy Foundation noticed as well. The organization had been very involved in the planning...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

New EU Filings

13 Aug 2025

• By Neena Brizmohun

Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

With Thyroid Petition Win, AbbVie Snares Itself; US FDA Sets Up Another Compounding Fight

13 Aug 2025

• By Manas Mishra

AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.